These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28800947)

  • 101. Tocilizumab in giant cell arteritis: an update for the clinician.
    Ford JA; Gewurz D; Gewurz-Singer O
    Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Biologic Therapy for the Treatment of Giant Cell Arteritis.
    Ostrowski RA; Bussey MR; Tehrani R; Jay W
    Neuroophthalmology; 2014; 38(3):107-112. PubMed ID: 27928284
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Biologic Therapies for Giant Cell Arteritis.
    Harrington R; Al Nokhatha SA; Conway R
    Biologics; 2021; 15():17-29. PubMed ID: 33442231
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Update on the management of giant cell arteritis.
    Roberts J; Clifford A
    Ther Adv Chronic Dis; 2017 Apr; 8(4-5):69-79. PubMed ID: 28491267
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Tocilizumab: a novel therapy for patients with large-vessel vasculitis.
    Salvarani C; Magnani L; Catanoso M; Pipitone N; Versari A; Dardani L; Pulsatelli L; Meliconi R; Boiardi L
    Rheumatology (Oxford); 2012 Jan; 51(1):151-6. PubMed ID: 22075063
    [TBL] [Abstract][Full Text] [Related]  

  • 106. [Physiopathology of giant cell arteritis: From inflammation to vascular remodeling].
    Régent A; Ly KH; Mouthon L
    Presse Med; 2019 Sep; 48(9):919-930. PubMed ID: 31543394
    [TBL] [Abstract][Full Text] [Related]  

  • 107. [Epidemiology and natural history of giant cell arteritis].
    Mahr A; Aouba A; Richebé P; Gonzalez-Chiappe S
    Rev Med Interne; 2017 Oct; 38(10):663-669. PubMed ID: 28457683
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved.
    Terrades-Garcia N; Cid MC
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii51-ii62. PubMed ID: 29982777
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Efficacy of tocilizumab in refractory giant cell arteritis.
    Vinit J; Bielefeld P; Muller G; Besancenot JF
    Joint Bone Spine; 2012 May; 79(3):317-8. PubMed ID: 22284606
    [TBL] [Abstract][Full Text] [Related]  

  • 110. [Polymyalgia rheumatica and temporal arteritis].
    Vos PA; Bijlsma JW; Derksen RH
    Ned Tijdschr Geneeskd; 2005 Aug; 149(35):1932-7. PubMed ID: 16159030
    [TBL] [Abstract][Full Text] [Related]  

  • 111. [Gynecologic vasculitis revealing a giant cell arteritis: A case report and literature review].
    Guillotin V; Mercie P; Duffau P
    Rev Med Interne; 2022 Mar; 43(3):181-184. PubMed ID: 35031140
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight: "Risk profiling for GC resistance in GCA".
    Liozon E; Dumonteil S; Parreau S; Gondran G; Bezanahary H; Palat S; Ly KH; Fauchais AL
    Semin Arthritis Rheum; 2020 Dec; 50(6):1252-1261. PubMed ID: 33065420
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
    de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
    Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
    [TBL] [Abstract][Full Text] [Related]  

  • 114. New treatment strategies in large-vessel vasculitis.
    Unizony S; Stone JH; Stone JR
    Curr Opin Rheumatol; 2013 Jan; 25(1):3-9. PubMed ID: 23114585
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009).
    Chandran A; Udayakumar PD; Kermani TA; Warrington KJ; Crowson CS; Matteson EL
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-98-102. PubMed ID: 26016757
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis.
    Lavergne A; Dumont A; Deshayes S; Boutemy J; Maigné G; Silva NM; Nguyen A; Gallou S; Philip R; Aouba A; de Boysson H
    Semin Arthritis Rheum; 2023 Jun; 60():152192. PubMed ID: 36963127
    [TBL] [Abstract][Full Text] [Related]  

  • 117. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.
    Langford CA; Cuthbertson D; Ytterberg SR; Khalidi N; Monach PA; Carette S; Seo P; Moreland LW; Weisman M; Koening CL; Sreih AG; Spiera R; McAlear CA; Warrington KJ; Pagnoux C; McKinnon K; Forbess LJ; Hoffman GS; Borchin R; Krischer JP; Merkel PA;
    Arthritis Rheumatol; 2017 Apr; 69(4):837-845. PubMed ID: 28133925
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Tocilizumab for giant cell arteritis: an amazing result.
    Işık M; Kılıç L; Doğan İ; Calgüneri M
    Rheumatol Int; 2013 Nov; 33(11):2961-2. PubMed ID: 22965672
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure.
    Robson JC; Almeida C; Dawson J; Bromhead A; Dures E; Guly C; Hoon E; Mackie S; Ndosi M; Pauling J; Hill C
    Rheumatology (Oxford); 2021 Oct; 60(10):4671-4680. PubMed ID: 33528002
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
    Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.